We Give Shareholders a Voice
Levi & Korsinsky announces it has commenced an investigation of Transgenomic Inc. (NASDAQCM: TBIO) concerning possible breaches of fiduciary duty by its Board of Directors.
The investigation concerns the discovery that Transgenomic violated its shareholder-approved compensation plan by granting its CEO excess compensation in the amount of 2,125,000 stock options since September 30, 2013.
To receive more information, please fill out the form.